Condition

Non Small Cell Lung Cancer NSCLC (1)

Overall Status

Recruiting (1)

Sign in for free

Phase

phase 3 (1)

Sponsor

AstraZeneca (1)

Collaborator

Intervention

abraxane + carboplatin (1)

durvalumab (1)

gemcitabine + carboplatin (1)

gemcitabine + cisplatin (1)

pemetrexed + carboplatin (1)

pemetrexed + cisplatin (1)

tremelimumab (1)

Study Documents

Intervention Type

drug (1)

Funder Type

Industry (1)

Study Type

Interventional (1)

non small cell lung cancer nsclc

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Non Small Cell Lung Cancer NSCLC Trial in Worldwide (Durvalumab, Tremelimumab, Abraxane + carboplatin)

Recruiting

Non Small Cell Lung Cancer NSCLC

Durvalumab
+6 more

Phoenix, Arizona
+181 more

Aug 17, 2022